[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 1986

Alterations in Cerebrospinal Fluid Concentrations of Somatostatinlike Immunoreactivity in Neuropsychiatric Disorders

Author Affiliations

From the Departments of Psychiatry (Drs Bissette and Nemeroff) and Pharmacology (Dr Nemeroff), and the Center for Aging and Human Development (Dr Nemeroff), Duke University Medical Center, Durham, NC; the Department of Psychiatry and Neurochemistry, University of Lund, Lund, Sweden (Dr Widerlöv); the Psychiatric Research Center, University of Uppsala, Uppsala, Sweden (Dr Walleús); the Department of Psychiatry and Neurochemistry (Dr Karlsson), and Lillhagen Hospital Department of Psychiatry (Dr Forsman), University of Gothenburg, Hisings Backa, Gothenburg, Sweden; and Sater Hospital, Sater, Sweden (Dr Eklund).

Arch Gen Psychiatry. 1986;43(12):1148-1151. doi:10.1001/archpsyc.1986.01800120034008
Abstract

• The concentration of somatostatinlike immunoreactivity in cerebrospinal fluid (CSF) from normal, healthy volunteers (n =10) and patients with DSM-III diagnoses of major depression (n=17), schizophrenia (n =11), or dementia (n =29) was measured by a sensitive and specific radioimmunoassay. Statistically significant decreases in CSF concentrations of somatostatinlike immunoreactivity were seen in all three patient populations when compared with controls. These findings confirm previous reports of decreased concentrations of somatostatinlike immunoreactivity in the CSF of patients with depression and dementia and extend this observation to patients with schizophrenia as well. These findings are concordant with the view that reductions in somatostatinlike immunoreactivity concentrations are associated with diseases in which cognitive function is disturbed.

×